The financial details of the contract have not been disclosed.
OctoPlus provides formulation development and clinical material manufacturing services, besides offering drug delivery technologies to develop controlled release versions of existing or new drugs.
The company manufactures Locteron, a controlled release formulation of interferon alpha to treat chronic hepatitis C, for Biolex.
Locteron’s Phase IIb clinical studies have showed superior clinical data.